MBX Biosciences, Inc. Common Stock (MBX) Metrics: History & Chart

MBX Biosciences, Inc. Common Stock(MBX)

Biotechnology · Carmel, IN

$56.07-2.47 (-4.22%)

Delayed quote: Oct 6, 2026, 12:55 PM EDT

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Carmel, IN

63 employees

mbxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steve Hoerter

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+1.74%
30D Total Return	-5.15%
YTD Total Return	+85.61%
1Y Total Return	+250.75%
3Y Total Return	N/A
5Y Total Return	N/A
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+85.61%
2025	+71.13%
2024	N/A
2023	N/A
2022	N/A
2021	N/A

CAGR TTM	+248.66%
CAGR 3Y	N/A
CAGR 5Y	N/A
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

MBX Valuation Metrics

MBX Stock Price Metrics

MBX Dividend Metrics

MBX Growth Rate Metrics

MBX Discounted Cash Flow Metrics

MBX Returns By Period

MBX Yearly Returns

MBX Average Annual Returns By Period (CAGR)

MBX Revenue Metrics

MBX PE Ratio Metrics

MBX PS Ratio Metrics

MBX PB Ratio Metrics

MBX Price to Free Cash Flow Ratio Metrics

MBX Debt to Equity Ratio Metrics

MBX PEG Ratio Metrics

MBX FCF Yield

MBX Earnings Yield

MBX EBITDA Yield

MBX OCF Yield

MBX EV/EBIT Ratio Metrics

MBX EV/EBITDA Ratio Metrics

MBX EV/Assets Ratio Metrics

MBX EV/Sales Ratio Metrics

MBX Current Ratio Metrics

MBX Quick Ratio Metrics

MBX ROIC Metrics

MBX Return on Assets Metrics

MBX Return on Equity Metrics

MBX Net Profit Margin Metrics

MBX Gross Profit Margin Metrics

MBX Tax Rate Metrics

PS Ratio	N/A
PS Ratio Avg TTM	N/A
PS Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

PB Ratio	6.82
PB Ratio Avg TTM	4.15
PB Ratio Avg 3Y	2.33
Current VS TTM Avg	+64.46%
Current VS 3Y Avg	+193.23%
Current VS 5Y Avg	+193.23%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.00
Debt/Equity Ratio Avg 3Y	0.00
Current VS TTM Avg	+161.27%
Current VS 3Y Avg	+677.38%
Current VS 5Y Avg	+763.76%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	6.29
Ev/Assets Ratio Avg TTM	3.69
Ev/Assets Ratio Avg 3Y	1.96
Current VS TTM Avg	+70.37%
Current VS 3Y Avg	+221.37%
Current VS 5Y Avg	+221.37%

Ev/Sales Ratio	N/A
Ev/Sales Ratio Avg TTM	N/A
Ev/Sales Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Current Ratio	18.08
Current Ratio Avg TTM	25.19
Current Ratio Avg 3Y	18.49
Current VS TTM Avg	-28.21%
Current VS 3Y Avg	-2.20%
Current VS 5Y Avg	+5.32%

Quick Ratio	18.08
Quick Ratio Avg TTM	25.19
Quick Ratio Avg 3Y	18.49
Current VS TTM Avg	-28.21%
Current VS 3Y Avg	-2.20%
Current VS 5Y Avg	+5.32%

ROIC	(28.60%)
ROIC Avg 3Y	(38.29%)
ROIC Avg 5Y	(38.29%)
Current VS 3Y Avg	+25.29%
Current VS 5Y Avg	+25.29%
Current VS 10Y Avg	+25.29%

ROA	(23.93%)
ROA Avg TTM	(6.64%)
ROA Avg 3Y	(5.97%)
Current VS TTM Avg	-260.17%
Current VS 3Y Avg	-300.88%
Current VS 5Y Avg	-337.32%

ROE	(25.47%)
ROE Avg TTM	(24.94%)
ROE Avg 3Y	(28.50%)
Current VS TTM Avg	-2.12%
Current VS 3Y Avg	+10.63%
Current VS 5Y Avg	+10.63%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A